LAVA Therapeutics (LVTX) Institutional Ownership → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free LVTX Stock Alerts $3.11 +0.03 (+0.97%) (As of 05/9/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for LAVA Therapeutics (NASDAQ:LVTX)Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$995.93KNumber ofInstitutional Sellers(last 12 months)0 Get LVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling LAVA Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LVTX Institutional Buying and Selling by Quarter Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide LAVA Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/10/2024 Pathway Financial Advisors LLC14,000$47K0.0%N/A0.000% 5/12/2023Bruce & Co. Inc.671,874$1.12M0.3%+571.9%2.650% 2/10/2023PNC Financial Services Group Inc.50,000$175K0.0%N/A0.197% 2/1/2023Bank of Montreal Can89,600$530K0.0%N/A0.353% 11/14/2022UBS Oconnor LLC75,000$343K0.0%N/A0.296% 10/28/2022Silverarc Capital Management LLC610,809$2.79M0.9%N/A2.409% Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/16/2022DAFNA Capital Management LLC128,335$379K0.1%-7.9%0.506% 8/15/2022Nantahala Capital Management LLC322,980$953K0.0%-3.3%1.274% 2/14/2022Point72 Asset Management L.P.119,152$655K0.0%-3.8%0.470% 11/15/2021Point72 Asset Management L.P.123,911$734K0.0%N/A0.489% 11/15/2021AXA S.A.229,121$1.36M0.0%+3.8%0.904% 11/12/2021Falcon Edge Capital LP140,229$830K0.1%-3.2%0.553% 8/17/2021Woodline Partners LP86,904$946K0.0%-23.3%0.343% 8/17/2021Millennium Management LLC138,831$1.51M0.0%-38.6%0.548% 8/16/2021Redmile Group LLC2,816,196$30.64M0.5%-0.3%11.108% 8/13/2021Geode Capital Management LLC12,997$141K0.0%N/A0.051% 8/11/2021 Bank of New York Mellon Corp25,288$275K0.0%-26.3%0.100% 8/10/2021Nicholas Investment Partners LP781,867$8.51M0.5%-4.0%3.084% 8/2/2021 New York State Common Retirement Fund19,136$208K0.0%-26.3%0.075% 5/27/2021Davidson Kempner Capital Management LP2,000$30K0.0%N/A0.008% 5/18/2021Millennium Management LLC226,205$3.44M0.0%N/A0.892% 5/18/2021Point72 Asset Management L.P.5,561$84K0.0%N/A0.022% 5/18/2021Tudor Investment Corp Et Al19,614$298K0.0%N/A0.077% 5/18/2021Redmile Group LLC2,824,409$42.90M0.6%N/A11.141% 5/18/2021Davidson Kempner Capital Management LP2,000$30K0.0%N/A0.008% 5/18/2021Citadel Advisors LLC60,442$918K0.0%N/A0.238% 5/18/2021Falcon Edge Capital LP150,454$2.29M0.1%N/A0.593% 5/17/2021Point72 Hong Kong Ltd9,355$142K0.0%N/A0.037% 5/17/2021Woodline Partners LP113,242$1.72M0.0%N/A0.447% 5/17/2021 Caas Capital Management LP30,000$456K0.0%N/A0.118% 5/17/2021Pinz Capital Management LP25,900$393K0.1%N/A0.102% 5/17/2021Sphera Funds Management LTD.213,894$3.25M0.2%N/A0.844% 5/17/2021Novo Holdings A S3,327,312$50.54M2.1%N/A13.124% 5/14/2021Nantahala Capital Management LLC381,227$5.79M0.2%N/A1.504% 5/14/2021Nicholas Investment Partners LP814,840$12.38M0.9%N/A3.214% 5/14/2021Monashee Investment Management LLC265,000$3.02M0.5%N/A1.045% 5/13/2021 Bank of New York Mellon Corp34,319$521K0.0%N/A0.135% 5/12/2021Pura Vida Investments LLC54,000$820K0.0%N/A0.213% (Data available from 1/1/2016 forward) LVTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LVTX shares? During the previous two years, the following institutional investors and hedge funds held shares of LAVA Therapeutics shares: Silverarc Capital Management LLC ($2.79M), Bruce & Co. Inc. ($1.12M), Nantahala Capital Management LLC ($953K), Bank of Montreal Can ($530K), DAFNA Capital Management LLC ($379K), UBS Oconnor LLC ($343K), and PNC Financial Services Group Inc. ($175K).Learn more on LVTX's institutional investors. Which institutional investors have been buying LAVA Therapeutics stock? The following institutional investors have purchased LAVA Therapeutics stock in the last 24 months: Silverarc Capital Management LLC ($610.81K), Bruce & Co. Inc. ($571.87K), Bank of Montreal Can ($89.60K), UBS Oconnor LLC ($75K), PNC Financial Services Group Inc. ($50K), and Pathway Financial Advisors LLC ($14K). How much institutional buying is happening at LAVA Therapeutics? Institutional investors have bought a total of 1,411,283 shares in the last 24 months. This purchase volume represents approximately $4.62M in transactions. Which LAVA Therapeutics major shareholders have been selling company stock? The following institutional investors have sold LAVA Therapeutics stock in the last 24 months: Nantahala Capital Management LLC ($11.18K), and DAFNA Capital Management LLC ($11.00K). How much institutional selling is happening at LAVA Therapeutics? Institutional investors have sold a total of 22,181 shares in the last 24 months. This volume of shares sold represents approximately $65.43K in transactions. Related Companies: Context Therapeutics Major Shareholders Grifols Major Shareholders NLS Pharmaceutics Major Shareholders Pharvaris Major Shareholders Tiziana Life Sciences Major Shareholders Alpha Tau Medical Major Shareholders Alvotech Major Shareholders American Oncology Network Major Shareholders Apollomics Major Shareholders BriaCell Therapeutics Major Shareholders This page (NASDAQ:LVTX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.